

PATENT SPECIFICATION

(11) 1242211

1242211

NO DRAWINGS

(21) Application No. 36270/67 (22) Filed 8 Aug. 1967
 (23) Complete Specification filed 23 July 1968
 (45) Complete Specification published 11 Aug. 1971
 (51) International Classification A 61 k 13/00
 (52) Index at acceptance
 ASB 201 20Y 213 215 21Y 24X 24Y 285 28Y 292 29Y
 36X 36Y 386 387 38Y 390 392 39X 422 42Y
 481 482 483 48Y 550 55Y 576 57Y 616 61Y
 644 64Y 763 766 767 77Y

(72) Inventors STEPHEN RAYMOND GUNNING and PHILIP SAXTON HARTLEY



(54) PHARMACEUTICAL COMPOSITION

(71) We, FISONS PHARMACEUTICALS LIMITED, a British Company, of 12 Derby Road, Loughborough, Leicestershire, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

10 The present invention relates to improved pharmaceutical compositions for oral inhalation.

15 More particularly the invention is concerned with pharmaceutical compositions which are to be dispersed into an air stream by a fluidisation technique which uses the inspiratory action of the inhaler as the principal source of energy. The fluidisation technique is that achieved when powder within a container is subjected to simultaneous rotation and vibration. Such fluidisation is achieved in the dispenser described in French Patent No. 1471722 which corresponds to British Patent Specification No. 1122284. An example of such a form of device is one which comprises a hollow 20 elongate housing having at both ends thereof one or more passageways adapted to permit the passage of air and having one end thereof adapted for insertion into the mouth and a propeller-like device rotatably mounted in the said housing on a rigid shaft mounted in said housing and co-axial with the longitudinal axis of the housing; said propeller-like device having, on the part thereof furthest from the end of the housing adapted for insertion into the mouth, mounting means adapted to receive a container, such as a gelatine capsule, for the medicament to be inhaled.

25 Medicaments for administration by inhalation should be of a controlled particle size in order to achieve maximum penetration into the lungs; a suitable particle size range being 0.01 to 10, usually 1—10, microns. However, powders in this particle size range are not readily fluidised by the above technique be-

cause of cohesive forces between the individual particles. 45

It has now been found that such particles may be rendered readily fluidisable using such fluidising techniques by mixing the finely divided medicament or pharmaceutically active material with a coarser carrier medium whose particles have sizes falling within a given range. 50

According to the invention, therefore, there is provided a pharmaceutical powder composition which comprises a mixture of a solid having an effective particle size as hereinafter defined in the range of 0.01 to 10 microns and a solid pharmaceutically acceptable water soluble carrier having an effective particle size as hereinafter defined in the range of from 30 to 80 microns. According to a specially preferred embodiment of the invention the composition is substantially free as hereinafter defined of particles in the effective size range 11 to 29 microns. 60

For the purpose of the present invention there is no distinction between a single particle of given size and an agglomerate of the same size which is composed of finer individual particles. The term "effective particle size" is therefore used herein and in the claims, where the context permits, to denote the apparent particle size of a body without distinction as to the number of individual particles which go to make up that body. The effective particle sizes quoted herein are those as measured with a Coulter counter. 70

75 In measuring particle sizes with a Coulter counter, the sample to be analysed is dispersed in an electrolyte into which dips a glass tube. The glass tube has a hole through the wall thereof with electrodes mounted on either side of the hole in the tube wall. The tube is immersed sufficiently for the hole and electrodes to be submerged in the liquid. The suspension is made to flow through the hole in the glass tube and as each particle passes through the 80

85

orifice it displaces its own volume of electrolyte, thus changing the resistance across the hole. This change in resistance is converted into a voltage pulse with an amplitude proportional to the particle volume. The pulses are fed to an electronic counter with an adjustable threshold level such that all pulses above the threshold are counted. By setting the threshold level at different values it is possible to determine the number of particles falling within given size ranges and thus the proportion of particles in a sample which fall outside a desired particle size range.

The composition may contain any of a wide variety of medicaments suitable for administration by inhalation, e.g. medicaments intended for alleviation of disorders of the bronchial tract or medicaments administered for systemic action. Particular examples of medicaments which may be employed in the composition of the invention are antianaphylactic agents such as sodium chromoglycate [sodium chromoglycate is the di-sodium salt of 1,3 - bis (2-carboxy chromone - 5 - yloxy) - 2 - hydroxypropane], sympathomimetic amines such as isoprenaline or ephedrine or salts thereof; or mixtures thereof; antibiotics such as tetracycline, steroids, enzymes, vitamins, antihistamines and mucolytics such as N-acetyl cysteine. The composition may contain more than one medicament in finely divided form. Thus, a composition may contain, for example, a mixture of sodium chromoglycate and isoprenaline sulphate. As stated above, the medicament should be in finely divided form having an effective particle size in the range 0.01—10, preferably 1—10 microns, and suitably at least 50% by weight of the finely divided medicament is in the effective particle size range 2—6 microns. Where the medicament is one of high specific activity, it may be desirable to dilute the medicament with an inert diluent of similar particle size. Such a composition should, of course, also contain a coarser carrier having an effective particle size in the range 30—80 microns.

The solid diluent or carrier in the composition will generally be a non-toxic material chemically inert to the medicament but may, if so desired, also comprise larger sized particles of the medicament. The carrier has an effective particle size in the range 30—80 microns preferably 30—70, especially 30—60 microns. Examples of water-soluble solid diluents or carriers which may be used in the composition of the invention include a dextran, mannitol and, preferably, lactose. A particularly preferred diluents or carrier is crystalline lactose. A particularly preferred diluents or carrier is crystalline lactose.

As indicated earlier, it is especially desired that the composition be substantially free from particles having an effective size in the range 1 to 29 microns. The term substantially

free is used herein an in the claims to denote that the composition contains less than 10%, preferably less than 5%, by weight thereof of particles having effective sizes in the range 11 to 29 microns.

The ratio of finely divided material containing or consisting of medicament, to carrier may vary depending upon the materials used. The optimum ratio will depend upon the nature of the medicament and carrier and the method by which the composition is to be applied. We have found that the use of from 10—75% by weight of finely divided material, e.g. medicament, to 90—25% by weight of carrier, preferably from 20 to 60% by weight of finely divided materials, e.g. about 35 to 50% by weight of medicament to 65 to 50% by weight of carrier, in general provides satisfactory results.

The finely divided medicament, or other finely divided material comprising medicament, may be prepared by direct milling down to the desired particle size range. The particulate carrier may be prepared by grinding the carrier and subsequently separating out the desired fraction by conventional methods, e.g. by air classification and sieving. The surface characteristics of individual particles of both the medicament and carrier may be modified by such conventional techniques as crystallisation, spray drying and precipitation.

The compositions may be prepared from the fine and coarse ingredients by mixing the ingredients together in a mixer, such as a planetary or other stirred mixer. The invention thus also provides a method for preparing a composition of the invention which comprises mixing together the finely divided material and the coarse carrier, after comminution and particle size classification of the ingredients if this is necessary. If desired, the surfaces of the particles of medicament and/or diluent and/or carrier may be coated with a pharmaceutically acceptable material, such as stearic acid, or polymers such as polyvinyl pyrrolidone. This coating procedure may serve incidentally to give a sustained release action to the medicament.

In addition to the medicament and carrier, the composition may contain other ingredients, such as colouring matter or flavouring agents such as saccharin, which are normally present in inhalant compositions. It is, however, preferred to use the minimum of such other ingredients and that, when present, they should have effective particle sizes in the range 30—80 microns.

The compositions according to the invention will generally be put up in gelatine, plastic or other capsules.

There is also provided, therefore, as a further feature of the invention, a dosage unit comprising a capsule containing a pharmaceutical composition comprising a mixture of a solid medicament having an effective particle

70

75

80

85

90

95

100

105

110

115

120

125

130

size in the range of from 0.01 to 10 microns and a solid pharmaceutically acceptable water soluble carrier having an effective particle size in the range of from 30 to 80 microns. The capsule will, just before use, be pierced.

5 The amount of composition contained in the capsule will, of course, to some extent depend on the specific activity of the medicament and the desired dosage. However, where possible 10 the capsule suitably contains from 10 to 100 mg. of the composition and for medicaments of high specific activity it maybe desirable to dilute the medicament with an inert diluent of similar particle size as described above.

15 Preferred compositions of the invention comprise a mixture of sodium chromoglycate, and optionally also isoprenaline sulphate, having an effective particle size in the range 0.01 to 10 microns and crystalline lactose having an effective particle size in the range 30 to 80 microns.

In order that the invention may be well understood, the following Examples of compositions according to the invention are given by 25 way of illustration only:

EXAMPLE 1

Commercially available ground crystalline lactose having an effective particle size of from 1 to 100 microns (less than 30% by weight 30 greater than 60 microns, not more than 30% by weight less than 30 microns) was passed through an air classifier, set to remove material having an effective particle size of less than 30 microns, the product from the air classifier 35 contained less than 4% by weight of material of less than 32 microns effective size. This product was then sieved through a sieve having a mesh aperture of 63 microns to produce a lactose product which contained less than 40 10% by weight of particles with an effective size less than 32 microns and less than 20% by weight with an effective particle size in excess of 62 microns as determined on an Alpine air jet sieve.

45 The medicament or other material such as lactose which was intended to form part of the finely divided material, was passed through a fluid energy mill in an air stream until the product contained at least 50% by weight of particles in the effective size range 2 — 6 microns as determined on a Coulter counter.

Compositions containing the desired proportions of the coarse and fine materials were mixed together in a planetary mixer and the

55 mixture then passed through a 30 mesh sieve (British Standard) to remove or break up aggregated particles.

The compositions were then put up in gelatine capsules containing about 40 mg of the composition (capsule approximately $\frac{1}{3}$ full) and the ease of emptying of the composition from the capsule determined. The ease of emptying was assessed by mounting a pierced capsule in the capsule holder of the powder insufflator of French Patent Specification No. 1471722 which corresponds to British Patent Specification No. 1122284. The insufflator was then mounted in a hole in the side wall of a chamber connected to a bellows. The bellows were designed to suck air through the chamber, and hence the insufflator acting as the air inlet thereinto, at a rate of 1 litre per second. Each suck of the bellows lasted one second.

70 The capsule was weighed prior to mounting in the insufflator. The bellows were then operated to give seven one second sucks and the capsule reweighed to determine the amount of powder removed from the capsule. The amount of powder removed is related to the ease of fluidisation of the powder.

75 The compositions prepared and tested are set out in Table I. By way of comparison a composition containing no coarse diluent was prepared and tested in each case. Those compositions containing the coarse carrier were all found to empty from the capsule at a satisfactory rate, in general from 85 to 90% of the composition, whereas in the absence of the coarse diluent the emptying rates were much lower, about 15% or less, and were unpredictable.

80 EXAMPLE 2

85 By way of comparison a further series of compositions were prepared which contained coarse carrier material which possessed an appreciable proportion of particles with an effective size outside the range 30 — 80 microns. The emptying rates for these compositions are set out in Table 2.

90 From these results it will be seen that the rate of emptying of a capsule, containing a composition which comprises an appreciable proportion of particles whose effective size fell outside the range 30 — 80 microns, was very low and unpredictable, thus rendering the administration of such compositions by inhalation unsatisfactory.

TABLE 1

| Fine material: nature of material and effective particle size | Parts by weight used | Coarse carrier: nature of material and effective particle size | Parts by weight used w |
|---|----------------------|--|------------------------|
| Sodium chromoglycate (1—10 μ , at least 50% w/w in the range 2—6 μ) | 20 | Crystalline lactose (32—63 μ) | 19.9 |
| Isoprenamine sulphate (1—10 μ , at least 50% w/w in the range 2—6 μ) | 0.1 | | |
| Isoprenamine sulphate (1—10 μ , at least 50% w/w in the range 2—6 μ) | 0.1 | Crystalline lactose (32—63 μ) | 19.9 |
| Crystalline lactose (1—10 μ , at least 50% w/w in the range 2—6 μ) | 20 | Crystalline lactose (32—63 μ) | |
| Tetracycline (1—10 μ , at least 50% w/w in the range 2—6 μ) | 14 | Crystalline lactose (32—63 μ) | 26 |
| Penicillin G, (1—10 μ , at least 50% w/w in the range 2—6 μ) | 10 | Crystalline lactose (32—63 μ) | 30 |

TABLE 2

| Nature of fine material | Effective particle size in microns | Parts by weight used | Nature of coarse material | Effective particle size in microns | Parts by weight used | % w/w of material removed from capsule |
|-------------------------|------------------------------------|----------------------|---------------------------|------------------------------------|----------------------|--|
| Sodium chromoglycate | 1—10, at least 50% w/w 2—6 | 20 | Crystalline lactose | 32—63 | 20 | 87.2 |
| " | " | 10 | " | Less than 30 | 30 | 0* |
| " | " | 30 | " | " | 10 | 10* |
| " | " | 20 | " | " | 20 | 0* |
| " | " | 0 | " | 1—100 | 40 | Totally unpredictable |
| " | " | 20 | " | 10—30 | 20 | 20* |
| " | " | 20 | " | 10—63 | 20 | 58.6 |

In the above Table the results marked * are unpredictable and many results were at total variance with any general trend which could be assessed. The results of these tests are therefore given as the general trend and not as a mean of the various results obtained.

Sodium chromoglycate having an effective particle size of from 0.01 to 10 microns is described and claimed in our co-pending application No. 8906/71 (serial No. 1,242,212).

WHAT WE CLAIM IS:—

1. A pharmaceutical powder composition for inhalation, which comprises a mixture of a solid finely divided medicament having an effective particle size, as hereinbefore defined, in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water soluble carrier having an effective particle size, as hereinbefore defined, in the range 30 — 80 microns. 5

10. 2. A composition as claimed in claim 1 which is substantially free, as hereinbefore defined, of particles having effective particle sizes, as hereinbefore defined, in the range 11 — 29 microns.

15. 3. A composition according to either of claims 1 or 2, wherein the finely divided medicament has an effective particle size, as hereinbefore defined, in the range 1—10 microns.

20. 4. A composition according to either of claims 1 or 2, wherein at least 50% by weight of the finely divided medicament has an effective particle size, as hereinbefore defined, in the range 2 — 6 microns.

25. 5. A composition according to any of the preceding claims, wherein the carrier has an effective particle size, as hereinbefore defined, in the range 30 — 70 microns.

30. 6. A composition according to any of the preceding claims wherein the finely divided medicament is diluted with a solid pharmaceutically acceptable water soluble diluent of the same effective particle size, as hereinbefore defined, as the medicament.

35. 7. A composition according to any of claims 1 — 5, comprising particles of medicament with an effective particle size, as hereinbefore defined, in the range 30 — 80 microns.

40. 8. A composition according to any of the preceding claims, wherein the carrier or diluent material comprises a dextran, mannitol or lactose.

45. 9. A composition according to claim 8, wherein the lactose is a crystalline lactose.

50. 10. A composition according to any of the preceding claims, wherein the medicament is sodium chromoglycate; isoprenaline sulphate; or salts thereof, or a mixture thereof.

55. 11. A composition according to any of the preceding claims, wherein the finely divided medicament is present in from 10—75% by weight and the carrier is present in from 90 — 25% by weight.

60. 12. A composition according to any of the preceding claims, wherein the surface characteristics of the medicament or carrier particles have been modified.

13. A composition according to claim 12, wherein the surfaces of the particles have been coated with polyvinyl pyrrolidone or stearic acid.

14. A pharmaceutical powder composition according to claim 1 and substantially as herein described. 65

15. A pharmaceutical powder composition according to claim 1 and substantially as herein described in either of Examples 1 or 2. 65

16. A dosage unit comprising a capsule containing a composition as claimed in any of the preceding claims. 70

17. A dosage unit as claimed in claim 16, wherein the capsule is pierced. 70

18. A method of dispersing a composition as claimed in claim 1 into an air stream, which comprises subjecting a dosage unit as claimed in claim 17 to simultaneous rotation and vibration. 75

19. A method for preparing a composition for inhalation, which comprises a mixture of a finely divided medicament having an effective particle size, as hereinbefore defined, in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water soluble carrier having an effective particle size, as hereinbefore defined, in the range 30 to 80 microns, which method comprises mixing together the finely divided medicament and the carrier. 80

20. A method according to claim 19, wherein the mixing is carried out in a stirred mixer. 80

21. A method according to either of claims 19 or 20, wherein the materials to be mixed are subjected to comminution and particle size classification prior to mixing. 90

22. A composition comprising a mixture of sodium chromoglycate having an effective particle size, as hereinbefore defined, in the range 0.01 to 10 microns and crystalline lactose having an effective particle size, as hereinbefore defined, in the range 30 to 80 microns. 95

23. A composition comprising a mixture of sodium chromoglycate and isoprenaline sulphate both having an effective particle size, as hereinbefore defined, in the range 0.01 to 10 microns and crystalline lactose having an effective particle size, as hereinbefore defined, in the range 30 to 80 microns. 100

24. A composition according to either Claim 22 or Claim 23, wherein the finely divided material is present in from 10—75% by weight and the carrier is present in from 90—25% by weight. 105

25. A composition according to any one of claims 1 to 14 or 22 to 24 comprising from 10 to 100 mg of the composition in a capsule. 110

F. MURPHY,
Chartered Patent Agent,
Agent for the Applicants,
Fisons Limited,
Harvest House,
Felixstowe,
Suffolk.